Information Provided By: 
Fly News Breaks for February 21, 2017
ANAB
Feb 21, 2017 | 06:28 EDT
Stifel analyst Thomas Shrader initiated AnaptyBio with a Buy and a $30 price target saying it is a unique antibody generation company capable of directed expansion of monoclonal antibodies (mAbs) around a starting point and views it as a potential game changer for the company and collaborators. Beyond its lead programs, Shrader expects a broad pipeline to emerge, and several impressive partners, including Celgene and Tesaro, have already inked deals potentially worth $1.2B in future milestones.
News For ANAB From the Last 2 Days
There are no results for your query ANAB
